Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial
Abstract Introduction The water‐soluble mangosteen pericarp extract's (WME) effect was investigated in Alzheimer's disease (AD). Methods The participants received 4 mg/kg/day of WME for 24 weeks (low dose, n = 33), 4 mg/kg/day for 12 weeks and then 8 mg/kg/day for 12 weeks (high dose, n = ...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12292 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850108092578004992 |
|---|---|
| author | Weerasak Muangpaisan Puvanant Wiputhanuphongs Nattapon Jaisupa Sarawut Junnu Jutima Samer Primchanien Moongkarndi Orawan Supapueng Chalobol Chalermsri Neelobol Neungton |
| author_facet | Weerasak Muangpaisan Puvanant Wiputhanuphongs Nattapon Jaisupa Sarawut Junnu Jutima Samer Primchanien Moongkarndi Orawan Supapueng Chalobol Chalermsri Neelobol Neungton |
| author_sort | Weerasak Muangpaisan |
| collection | DOAJ |
| description | Abstract Introduction The water‐soluble mangosteen pericarp extract's (WME) effect was investigated in Alzheimer's disease (AD). Methods The participants received 4 mg/kg/day of WME for 24 weeks (low dose, n = 33), 4 mg/kg/day for 12 weeks and then 8 mg/kg/day for 12 weeks (high dose, n = 33); or a placebo (n = 42). The outcomes were neuropsychiatric test scores, safety, tolerability, and the blood 4‐hydroxynonenal level. Results The proportion of participants who achieved the minimum clinically important difference for the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog; –2.6 points) at 24 weeks was significantly higher in the low‐dose group (and a trend in the high‐dose group) than in the placebo group. WME appeared safe and well tolerated. At 24 weeks, the 4‐hydroxynonenal level declined in both intervention groups. The participants with a 5% reduction in this level showed greater ADAS‐Cog improvements. Conclusion WME is a safe and well‐tolerated cognitive enhancer in AD with varying benefits across individuals based on antioxidative response. |
| format | Article |
| id | doaj-art-773408a9fb7b46bea6152d9bfa1fd454 |
| institution | OA Journals |
| issn | 2352-8737 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj-art-773408a9fb7b46bea6152d9bfa1fd4542025-08-20T02:38:27ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372022-01-0181n/an/a10.1002/trc2.12292Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trialWeerasak Muangpaisan0Puvanant Wiputhanuphongs1Nattapon Jaisupa2Sarawut Junnu3Jutima Samer4Primchanien Moongkarndi5Orawan Supapueng6Chalobol Chalermsri7Neelobol Neungton8Department of Preventive and Social Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok ThailandDepartment of Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok ThailandDepartment of Pharmacology Phramongkutklao College of Medicine Bangkok ThailandDepartment of Biochemistry Faculty of Medicine Siriraj Hospital Mahidol University Bangkok ThailandDepartment of Physiology Faculty of Pharmacy Mahidol University Bangkok ThailandDepartment of Microbiology Faculty of Pharmacy Mahidol University Bangkok ThailandDivision of Clinical Epidemiology Department of Research Faculty of Medicine Siriraj Hospital Mahidol University Bangkok ThailandDepartment of Preventive and Social Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok ThailandDepartment of Biochemistry Faculty of Medicine Siriraj Hospital Mahidol University Bangkok ThailandAbstract Introduction The water‐soluble mangosteen pericarp extract's (WME) effect was investigated in Alzheimer's disease (AD). Methods The participants received 4 mg/kg/day of WME for 24 weeks (low dose, n = 33), 4 mg/kg/day for 12 weeks and then 8 mg/kg/day for 12 weeks (high dose, n = 33); or a placebo (n = 42). The outcomes were neuropsychiatric test scores, safety, tolerability, and the blood 4‐hydroxynonenal level. Results The proportion of participants who achieved the minimum clinically important difference for the Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS‐Cog; –2.6 points) at 24 weeks was significantly higher in the low‐dose group (and a trend in the high‐dose group) than in the placebo group. WME appeared safe and well tolerated. At 24 weeks, the 4‐hydroxynonenal level declined in both intervention groups. The participants with a 5% reduction in this level showed greater ADAS‐Cog improvements. Conclusion WME is a safe and well‐tolerated cognitive enhancer in AD with varying benefits across individuals based on antioxidative response.https://doi.org/10.1002/trc2.12292Alzheimer's diseaseclinical trialcognitionGarcinia mangostanamangosteen extractolder adults |
| spellingShingle | Weerasak Muangpaisan Puvanant Wiputhanuphongs Nattapon Jaisupa Sarawut Junnu Jutima Samer Primchanien Moongkarndi Orawan Supapueng Chalobol Chalermsri Neelobol Neungton Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial Alzheimer’s & Dementia: Translational Research & Clinical Interventions Alzheimer's disease clinical trial cognition Garcinia mangostana mangosteen extract older adults |
| title | Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial |
| title_full | Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial |
| title_fullStr | Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial |
| title_full_unstemmed | Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial |
| title_short | Effects of water‐soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate Alzheimer's disease (WECAN‐AD): A randomized controlled trial |
| title_sort | effects of water soluble mangosteen extract on cognitive function and neuropsychiatric symptoms in patients with mild to moderate alzheimer s disease wecan ad a randomized controlled trial |
| topic | Alzheimer's disease clinical trial cognition Garcinia mangostana mangosteen extract older adults |
| url | https://doi.org/10.1002/trc2.12292 |
| work_keys_str_mv | AT weerasakmuangpaisan effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT puvanantwiputhanuphongs effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT nattaponjaisupa effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT sarawutjunnu effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT jutimasamer effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT primchanienmoongkarndi effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT orawansupapueng effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT chalobolchalermsri effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial AT neelobolneungton effectsofwatersolublemangosteenextractoncognitivefunctionandneuropsychiatricsymptomsinpatientswithmildtomoderatealzheimersdiseasewecanadarandomizedcontrolledtrial |